title: [Hormonal correction of the resident microflora of the vagina and uterus cervix in women with chronic cervicitis].
abstract: Clinical, microbiological and hormonal examination of women with chronic cervicitis revealed lesions in the upper section of the reproductive tract in a high proportion of those examined, hormonal disturbances being registered in 96.7% of women. Dysbiotic manifestations (suppression of lacto- and bifidoflora and the excessive growth of opportunistic microorganisms) in the uterus cervix and vagina observed in patients with chronic cervititis were not associated with the etiology of the inflammatory process. The degree of dysmicrobiocenosis in the lower section of the genital tract in women with chronic cervicitis depends on the character of hormonal disturbances. The most significant inhibition of the resident flora was observed when ovarian dysfunction occurred and less significant--in cases of hyperprolactinemia and changes in the level of hypophysial hormones. Hormonal disturbances led to contamination of vagina and cervical canal with opportunistic microorganisms that was inversely proportional to the presence of lactic acid bacteria and bifidobacteria in these organs. Complex therapy of women with chronic cervicitis with the use of preparations for the correction of hormonal disturbances made it possible to restore the normal microflora of the genital tract and to improve the results of treatment.
authors.affiliation: State Medical Academy, Chelyabinsk, Russia.
authors.forename: I I
authors.initials: II
authors.lastname: Dolgushin
authors.forename: S L
authors.initials: SL
authors.lastname: Chernykh
authors.forename: V F
authors.initials: VF
authors.lastname: Dolgushina
mesh_terms: D001971:Bromocriptine / Q000627:therapeutic use; D002584:Cervix Uteri / Q000378:metabolism / Q000382:microbiology*; D002908:Chronic Disease; D003277:Contraceptives, Oral, Combined / Q000627:therapeutic use; D003280:Contraceptives, Oral, Synthetic / Q000627:therapeutic use; D017373:Cyproterone Acetate / Q000627:therapeutic use; D004338:Drug Combinations; D004958:Estradiol / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D019304:Ethinyl Estradiol-Norgestrel Combination / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006727:Hormone Antagonists / Q000627:therapeutic use; D006728:Hormones / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D002575:Uterine Cervicitis / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D014621:Vagina / Q000378:metabolism / Q000382:microbiology*
chemical_list: D003277:Contraceptives, Oral, Combined; D003280:Contraceptives, Oral, Synthetic; D004338:Drug Combinations; D006727:Hormone Antagonists; D006728:Hormones; C103294:estradiol valerate, cyproterone acetate drug combination; D001971:Bromocriptine; D011374:Progesterone; D017373:Cyproterone Acetate; D004958:Estradiol; D019304:Ethinyl Estradiol-Norgestrel Combination; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone